Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 03, 2024 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials

Aptose's AML drug tuspetinib selected for NCI's prestigious clinical research program for ability to target broad spectrum of AML and MDS populations
November 25, 2024 16:15 ET | Source: Aptose Biosciences, Inc.

Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering

Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
November 22, 2024 08:00 ET | Source: Aptose Biosciences, Inc.

Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering

Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
November 20, 2024 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy

Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
November 08, 2024 16:01 ET | Source: Aptose Biosciences, Inc.

Aptose Reports Results for the Third Quarter 2024

SAN DIEGO and TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
September 05, 2024 16:15 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Results from Special Meeting of Shareholders

Aptose Announces Results from Special Meeting of Shareholders
August 30, 2024 16:30 ET | Source: Aptose Biosciences, Inc.

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
August 15, 2024 16:30 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Adjournment of its Special Meeting of Shareholders

Aptose Announces Adjournment of its Special Meeting of Shareholders
August 08, 2024 17:06 ET | Source: Aptose Biosciences, Inc.

Aptose Reports Results for the Second Quarter 2024

Aptose Reports Results for the Second Quarter 2024
July 19, 2024 17:00 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Receipt of Deficiency Notice from Nasdaq

SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...